{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:01:54Z","timestamp":1791925314739,"version":"4.3.4"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004254","name":"MOR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004254","name":"MOR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004254","name":"MOR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.neuropharm.2019.04.025","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:43:40Z","timestamp":1556221420000},"page":"107619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Combining opioids and non-opioids for pain management: Current status"],"prefix":"10.1016","volume":"158","author":[{"given":"Jun-Xu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.04.025_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.110.169276","article-title":"Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy","volume":"335","author":"Banks","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib3","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/ALN.0b013e31825681cb","article-title":"Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials","volume":"116","author":"Blaudszun","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coph.2009.09.009","article-title":"Cannabinoid-opioid interactions during neuropathic pain and analgesia","volume":"10","author":"Bushlin","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","article-title":"Buprenorphine-naloxone therapy in pain management","volume":"120","author":"Chen","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","article-title":"Naloxegol for opioid-induced constipation in patients with noncancer pain","volume":"370","author":"Chey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/bja\/81.1.58","article-title":"Opioid tolerance: the clinical perspective","volume":"81","author":"Collett","year":"1998","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/JPR.S132026","article-title":"Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis","volume":"10","author":"Comi","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1526-4637.2001.01026.x","article-title":"Opioid drugs: a comparative survey of therapeutic and \"street\" use","volume":"2","author":"Cowan","year":"2001","journal-title":"Pain Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.112.194308","article-title":"Roles of mu-opioid receptors and nociceptin\/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates","volume":"343","author":"Cremeans","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib15","doi-asserted-by":"crossref","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","article-title":"A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates","volume":"113","author":"Ding","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00000658-196503000-00019","article-title":"Primary regulation of histamine metabolism by the liver","volume":"161","author":"Drapanas","year":"1965","journal-title":"Ann. Surg."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FBP.0b013e328348ed08","article-title":"Opioid antinociception, tolerance and dependence: interactions with the N-methyl-D-aspartate system in mice","volume":"22","author":"Dykstra","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/nm.4426","article-title":"Rationalizing combination therapies","volume":"23","author":"Editorial","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/bja\/aes344","article-title":"Efficacy of adding clonidine to intrathecal morphine in acute postoperative pain: meta-analysis","volume":"110","author":"Engelman","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ddr.21300","article-title":"Antinociceptive interactions between meloxicam and gabapentin in neuropathic pain depend on the ratio used in combination in rats","volume":"77","author":"Espinosa-Juarez","year":"2016","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1526-4637.2010.00939.x","article-title":"A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain","volume":"11","author":"Farrar","year":"2010","journal-title":"Pain Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib22","first-page":"111","article-title":"Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain","volume":"4","author":"Ferrari","year":"2011","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/187152711796235050","article-title":"Preclinical assessment of drug combinations for the treatment of pain: isobolographic and dose-addition analysis of the opioidergic system","volume":"10","author":"Fischer","year":"2011","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jpain.2005.02.003","article-title":"Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice","volume":"6","author":"Fischer","year":"2005","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib25","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1124\/jpet.106.101683","article-title":"Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception","volume":"318","author":"Fischer","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.neuropharm.2009.08.005","article-title":"Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: interactive effects","volume":"58","author":"Fischer","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00213-013-3396-y","article-title":"Assessment of the effects of contingent histamine injections on the reinforcing effectiveness of cocaine using behavioral economic and progressive-ratio designs","volume":"231","author":"Freeman","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib28","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","article-title":"Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys","volume":"231","author":"Freeman","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.pain.2005.03.004","article-title":"MorphiDex (morphine sulfate\/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance","volume":"115","author":"Galer","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S1474-4422(13)70193-5","article-title":"Combination pharmacotherapy for management of chronic pain: from bench to bedside","volume":"12","author":"Gilron","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-3959(90)90062-I","article-title":"Self-administration of morphine in bone marrow transplant patients reduces drug requirement","volume":"40","author":"Hill","year":"1990","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1999.tb09344.x","article-title":"Novel selective compounds for the investigation of imidazoline receptors","volume":"881","author":"Hudson","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib33","first-page":"49","article-title":"The continuing interrelationship of CPDD and NIDDK","volume":"119","author":"Jacobson","year":"1992","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0269216317711826","article-title":"Opioids combined with antidepressants or antiepileptic drugs for cancer pain: systematic review and meta-analysis","volume":"32","author":"Kane","year":"2018","journal-title":"Palliat. Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1213\/ANE.0b013e3181cde882","article-title":"The development of new analgesics over the past 50 years: a lack of real breakthrough drugs","volume":"110","author":"Kissin","year":"2010","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2253-15-18","article-title":"Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section","volume":"15","author":"Koju","year":"2015","journal-title":"BMC Anesthesiol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib37","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1111\/bph.12728","article-title":"Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats","volume":"171","author":"Lanza","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2019.04.025_bib91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00001503-199810000-00016","article-title":"Side-effects of opioids in chronic pain treatment","volume":"11","author":"Lawlor","year":"1998","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.03.009","article-title":"Imidazoline I2 receptors: an update","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib39","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.12555","article-title":"Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain","volume":"171","author":"Li","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2011.07.041","article-title":"Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I(2) receptor ligands","volume":"669","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","article-title":"Abuse-deterrent opioid formulations","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1050","article-title":"The president's commission on combating drug addiction and the opioid crisis: origins and recommendations","volume":"103","author":"Madras","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.114.216648","article-title":"Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists","volume":"351","author":"Maguire","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2017.11.038","article-title":"Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio","volume":"819","author":"Maguire","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2016.06.012","article-title":"Recent advances in abuse-deterrent technologies for the delivery of opioids","volume":"510","author":"Maincent","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/bja\/aew391","article-title":"Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials","volume":"118","author":"Martinez","year":"2017","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10010020","article-title":"Pharmacokinetics and pharmacodynamics of (S)-Ketoprofen Co-administered with caffeine: a preclinical study in arthritic rats","volume":"10","author":"Medina-Lopez","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib49","first-page":"151","article-title":"CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats","volume":"5","author":"Meregalli","year":"2012","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jsps.2015.06.005","article-title":"Effect of tramadol on metamizol pharmacokinetics and pharmacodynamics after single and repeated administrations in arthritic rats","volume":"24","author":"Moreno-Rocha","year":"2016","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib92","series-title":"Pain Management Research Portfolio Online Reporting Tools","author":"National Institutes of Health","year":"2013"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2008.11.004","article-title":"Role of delta opioid efficacy as a determinant of mu\/delta opioid interactions in rhesus monkeys","volume":"602","author":"Negus","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib52","first-page":"867067","article-title":"Interaction between mu and delta opioid receptor agonists in an assay of capsaicin-induced thermal allodynia in rhesus monkeys","author":"Negus","year":"2012","journal-title":"Pain Res Treat"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0013088","article-title":"Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability","volume":"16","author":"Negus","year":"2008","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib54","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/npp.2017.51","article-title":"Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis","volume":"42","author":"Nielsen","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sjpain.2011.05.008","article-title":"Parenteral opioids in emergency medicine - a systematic review of efficacy and safety","volume":"2","author":"Niemi-Murola","year":"2011","journal-title":"Scand J Pain"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib56","series-title":"Long-term Opioid Management for Chronic Noncancer Pain","first-page":"CD006605","author":"Noble","year":"2010"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib57","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.phymed.2013.10.021","article-title":"Withania somnifera root extract prolongs analgesia and suppresses hyperalgesia in mice treated with morphine","volume":"21","author":"Orru","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib58","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1177\/2050640618796748","article-title":"New developments in the treatment of opioid-induced gastrointestinal symptoms","volume":"6","author":"Pannemans","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1901\/jeab.2010.93-203","article-title":"A choice procedure to assess the aversive effects of drugs in rodents","volume":"93","author":"Podlesnik","year":"2010","journal-title":"J. Exp. Anal. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib60","first-page":"49","article-title":"Tolerance to opioid analgesics: clinical aspects","volume":"21","author":"Portenoy","year":"1994","journal-title":"Can. Surv."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1358\/dot.2010.46.6.1470106","article-title":"Oxycodone combinations for pain relief","volume":"46","author":"Raffa","year":"2010","journal-title":"Drugs Today"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1345\/aph.1E309","article-title":"Pharmacologic treatment of opioid-induced sedation in chronic pain","volume":"39","author":"Reissig","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1037\/a0013628","article-title":"Opioids and the treatment of chronic pain: controversies, current status, and future directions","volume":"16","author":"Rosenblum","year":"2008","journal-title":"Exp. Clin. Psychopharmacol"},{"issue":"Suppl. 10","key":"10.1016\/j.neuropharm.2019.04.025_bib64","article-title":"A randomized, placebo-controlled, double-blind, phase II clinical trial of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes","volume":"69","author":"Rovati","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002018-199207030-00005","article-title":"Adverse effects of systemic opioid analgesics","volume":"7","author":"Schug","year":"1992","journal-title":"Drug Saf."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.116.232421","article-title":"Antinociceptive interactions between the imidazoline I2 receptor agonist 2-BFI and opioids in rats: role of efficacy at the mu-opioid receptor","volume":"357","author":"Siemian","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.36076\/ppj.2008\/11\/201","article-title":"Combination opioid analgesics","volume":"11","author":"Smith","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib68","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.aai8636","article-title":"A nontoxic pain killer designed by modeling of pathological receptor conformations","volume":"355","author":"Spahn","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib69","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1038\/s41598-018-27313-4","article-title":"Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist","volume":"8","author":"Spahn","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib70","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/2050640615604543","article-title":"Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response","volume":"3","author":"Tack","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib71","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/FBP.0000000000000206","article-title":"Antinociceptive effects of imidazoline I2 receptor agonists in the formalin test in rats","volume":"27","author":"Thorn","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib72","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s00213-015-3983-1","article-title":"Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: interactions with oxycodone","volume":"232","author":"Thorn","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib73","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/bph.13435","article-title":"Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural\/physical dependence on morphine in rats","volume":"173","author":"Thorn","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib74","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejphar.2011.09.173","article-title":"Effects of imidazoline I(2) receptor ligands on morphine- and tramadol-induced antinociception in rats","volume":"670","author":"Thorn","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib75","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/00003246-200006000-00079","article-title":"Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit","volume":"28","author":"Tobias","year":"2000","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pharmthera.2018.06.002","article-title":"Antiepileptic drugs as analgesics\/adjuvants in inflammatory pain: current preclinical evidence","volume":"192","author":"Tomic","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib77","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","article-title":"Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats","volume":"234","author":"Townsend","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.1824728","article-title":"Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801","volume":"251","author":"Trujillo","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib79","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(11)60402-9","article-title":"Treatment of chronic non-cancer pain","volume":"377","author":"Turk","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib80","first-page":"93","article-title":"WHO guidelines for the use of analgesics in cancer pain","volume":"7","author":"Ventafridda","year":"1985","journal-title":"Int. J. Tissue React."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.04.025_bib81","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib82","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib83","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M18-1397","article-title":"Overdose prevention through medical treatment of opioid use disorders","volume":"169","author":"Volkow","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib84","first-page":"261","article-title":"Acute and chronic opioid tolerance: a pharmacological review","volume":"32","author":"Wang","year":"1994","journal-title":"Acta Anaesthesiol. Sin."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib85","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/apt.12899","article-title":"Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation","volume":"40","author":"Webster","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/09540260902782794","article-title":"Interaction of the cannabinoid and opioid systems in the modulation of nociception","volume":"21","author":"Welch","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib87","first-page":"588","article-title":"Cancer pain management: opioid analgesics, Part 2","volume":"8","author":"Wickham","year":"2017","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.neuropharm.2019.04.025_bib88","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF01568465","article-title":"A psychodynamic study of a patient during experimental self-regulated re-addiction to morphine","volume":"26","author":"Wikler","year":"1952","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib89","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1021\/cn300049m","article-title":"Clinically employed opioid analgesics produce antinociception via mu-delta opioid receptor heteromers in Rhesus monkeys","volume":"3","author":"Yekkirala","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.025_bib90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/dmd.118.084905","article-title":"Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and drug administration in 2017","volume":"47","author":"Yu","year":"2019","journal-title":"Drug Metab. Dispos."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818309195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818309195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:00:09Z","timestamp":1758438009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818309195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":92,"alternative-id":["S0028390818309195"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.025","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining opioids and non-opioids for pain management: Current status","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107619"}}